Thermo Fisher Scientific Sees $4M in Bullish Call Activity as Stock Climbs Nearly 3%

By TrendSpider Editor

Thermo Fisher Scientific (TMO) attracted significant unusual options activity on Thursday, with five call contracts totaling $4,084,391.60 in combined premium as the stock gained 2.99% to trade at $506.75. The dominant trade was a $3,910,000 in-the-money call sweep at the $500 strike expiring Septem

Thermo Fisher Scientific Sees $4M in Bullish Call Activity as Stock Climbs Nearly 3%

Thermo Fisher Scientific (TMO) attracted significant unusual options activity on Thursday, with five call contracts totaling $4,084,391.60 in combined premium as the stock gained 2.99% to trade at $506.75. The dominant trade was a $3,910,000 in-the-money call sweep at the $500 strike expiring September 18, 2026, signaling that at least one large player is positioning for continued upside. With TMO currently sitting in the middle of its 52-week range of $393.00 to $643.99, there is meaningful room to run if bullish momentum holds.

Key Drivers of the TMO Stock Move

• Main Catalyst: Five unusual call contracts printed across multiple strikes and expirations, generating over $4 million in total premium. The standout was a single $500 strike call expiring September 18, 2026, with a size of 920 contracts and open interest coverage of 57%, followed by four additional calls across strikes ranging from $420 to $570.
• Bull Case: Every single one of the five flagged contracts is a call, making this a purely one-sided bullish flow with zero puts recorded. The largest contract is in-the-money at current prices, and the $420 strike expiring June 17, 2027 is also in-the-money, suggesting conviction across multiple time horizons. The stock's 2.99% gain on the day reinforces the directional bias.
• Bear Case: The $530, $560, and $570 strike calls are all currently out-of-the-money, meaning they require additional price appreciation to become profitable at expiration. TMO is still roughly 21% below its 52-week high of $643.99, and the stock would need to reclaim significant technical ground to validate the more aggressive upside bets in this flow.

The forward setup for TMO looks constructive based on today's price action and options positioning. The concentration of premium in the September 2026 expiration suggests traders are not looking for an overnight move but rather a multi-month recovery trade. TMO has faced macro headwinds in the life sciences tools space over the past year, with the stock's 52-week low of $393.00 reflecting the sector-wide pressure on research and biopharma spending. A stabilization or rebound in end-market demand, particularly from pharmaceutical and biotech customers, would be the fundamental catalyst needed to justify the bullish positioning seen today.

TMO Unusual Options Activity

All five flagged contracts on Thursday were calls, with no put activity recorded. Here is a breakdown of each contract:

• Call, $500 Strike, Expires September 18, 2026: Volume of 920 contracts, open interest coverage of 57%, in-the-money. This single contract accounted for $3,910,000 of the total $4,084,391.60 in combined premium, making it the dominant trade of the session.
• Call, $530 Strike, Expires July 10, 2026: Volume of 38 contracts, open interest coverage of 1,900%, out-of-the-money. The extreme open interest ratio suggests a very small existing OI base with a notable spike in activity.
• Call, $420 Strike, Expires June 17, 2027: Volume of 3 contracts, open interest coverage of 1,000%, in-the-money. Despite the small size, the 1,000% OI ratio flags this as unusual relative to existing positioning.
• Call, $570 Strike, Expires August 21, 2026: Volume of 52 contracts, open interest coverage of 1,000%, out-of-the-money.
• Call, $560 Strike, Expires August 21, 2026: Volume of 50 contracts, open interest coverage of 556%, out-of-the-money.

TMO Seasonality

Late June and the lead-up to second-quarter earnings have historically been an active period for institutional positioning in large-cap healthcare and life sciences names. Options flow concentrated in the September expiration, as seen in today's dominant trade, is consistent with traders looking to capture any positive surprise from a mid-summer earnings catalyst.

TMO Relative Performance

TMO's 2.99% gain on Thursday places it as an outperformer on the session relative to the broader healthcare sector, which tends to move more modestly on days without direct fundamental catalysts. Trading at $506.75, TMO sits approximately 28.6% above its 52-week low of $393.00 but remains roughly 21.5% below its 52-week high of $643.99, leaving it in recovery territory and giving the bullish options flow a plausible technical narrative to work with.